As we previously have shown that the prognostic impact of recurrent gene mutations in CLL is highly dependent on IGHV gene SHM status [22], we investigated if ATM mutations affected clinical outcome when patients were stratified into the U-CLL and M-CLL subgroups, again focusing primarily on Binet stage A CLL. This evidence concerns the gene ATM and B-cell chronic lymphocytic leukemia.